14733-77-8

Basic information

• Product Name: 2(3H)-Benzoxazolone,5-amino-(9CI)
• Synonyms: 2(3H)-Benzoxazolone,5-amino-(9CI);5-Aminobenzoxazol-2(3H)-one;2(3H)-Benzoxazolone, 5-amino-;2-Benzoxazolinone, 5-amino-;5-Amino-2-benzoxazolinone;5-Amino-2-benzoxazolone;5-Aminobenzoxazolin-2-one;5-Aminobenzoxazolone
• CAS NO: 14733-77-8
• Molecular Formula: C₇H₆N₂O₂
• Molecular Weight: 150.14
• Product Categories: AMINEPRIMARY
• Mol File: 14733-77-8.mol
• Article Data: 5

Chemical Properties

• Melting Point: 206-208 °C
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.438g/cm³
• Refractive Index: 1.659
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9.07±0.70(Predicted)
• CAS DataBase Reference: 2(3H)-Benzoxazolone,5-amino-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2(3H)-Benzoxazolone,5-amino-(9CI)(14733-77-8)
• EPA Substance Registry System: 2(3H)-Benzoxazolone,5-amino-(9CI)(14733-77-8)

Safety Data

• Hazardous Substances Data: 14733-77-8(Hazardous Substances Data)

Usage

Uses

5-Amino-2(3h)-Benzoxazolone is used in preparation of Pyridazinone derivatives as Nav1.1 activator.

InChI:InChI=1/C7H6N2O2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,8H2,(H,9,10)

Upstream product

• 64037-26-9 benzooxazole-2,5-diamine 
• 99-57-0 2-hydroxy-5-nitroaniline 
• 64037-16-7 5-nitro-benzooxazol-2-ylamine 
• 3889-13-2 5-nitro-3H-benzooxazol-2-one 

Downstream Products

• 1357101-83-7 N₂-(4-tert-butoxycarbonyl-3,5-dimethyl)phenyl-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine 
• 1357101-80-4 N₂-(3,4-dimethyl-5-hydroxymethyl)phenyl-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine 
• 1357101-78-0 N₂-(3-carboxy-4,5-dimethyl)phenyl-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine 
• 1357101-77-9 N₂-(3,4-dimethyl-5-methoxycarbonyl)phenyl-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine 
• 1357101-76-8 N₂-(3,5-dimethyl-4-methoxymethyl)phenyl-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine 
• 1357101-75-7 N₂-(3,5-dimethyl-4-hydroxymethyl)phenyl-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine 
• 1357101-73-5 N₂-(4-carboxy-3,5-dimethyl)phenyl-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine 
• 1357103-85-5 di-tert-butyl (5-(2-(4-fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)-2-oxobenzo[d]oxazol-3(2H)-yl)methyl phosphate 
• 1236666-76-4 N₂-(3,4,5-trimethyl)phenyl-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine 
• 1236667-40-5 5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methylpyrimidin-4-yl)amino)benzo[d]oxazol-2(3H)-one 
• 1236670-87-3 2-chloro-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-4-pyrimidineamine 
• 1187889-72-0 3-oxo-N-(2-oxo-2,3-dihydro-benzooxazol-5-yl)-3-[4-(2-trifluoromethyl-benzoyl)-piperazin-1-yl]-propionamide 
• 14733-73-4 5-bromo-1,3-benzoxazol-2(3H)-one 

Relevant articles and documents

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of Formulas I-VI, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth. Formula I is exemplified below: Formula (i)

2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to novel pyrimide derivatives of formula (I): that are useful as kinase inhibitors. More particularly, the present invention relates to novel pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders.

Benzimidazole derivatives, their preparation and use

A compound having the formula STR1 wherein R 1 is hydrogen, NH 2 or C 1-6 -alkyl which may be branched;X is O, S, NCN;Y is O, S;R 4, R 5, R 6 and R 7 independently of each other are hydrogen, halogen, CF 3, NO 2, NH 2, OH, C 1-6 -alkoxy, C( O)-phenyl or SO 2 NR I R II wherein R I and R II independently are hydrogen or C 1-6 -alkyl;R 11 is hydrogen, halogen, NO 2 or SO 2 NR''R"" wherein R'' and R"" independently are hydrogen or C 1-6 -alkyl;R 13 is hydrogen, halogen, phenyl, CF 3, NO 2 ;R 12 is hydrogen or together with R 13 forms a C 4-7 -carbocyclic ring which may be aromatic or partially saturated;R 14 is hydrogen or together with R 13 forms a C 4-7 -carbocyclic ring which may be aromatic or partially saturated;pharmaceutical compositions thereof,and a method of treating a disease in a mammal, including a human, responsive to opening of potassium channels, which comprises administering to a mammal in need thereof an effective amount of a compound as first above indicated, are disclosed.